Technology | Stents Peripheral | October 05, 2018

Veryan Medical's BioMimics 3D Stent Receives PMA Approval

Three-dimensional helical shape of peripheral stent designed to promote swirling flow and elevate wall shear

Veryan Medical's BioMimics 3D Stent Receives PMA Approval

October 5, 2018 — Veryan Medical Ltd has received Premarket Approval (PMA) for the BioMimics 3D Vascular Stent System from the U.S. Food & Drug Administration (FDA). The device is approved for the treatment of symptomatic de novo or restenotic lesions in the native superficial femoral artery and/or proximal popliteal artery.

The BioMimics 3D stent has a three-dimensional helical shape, designed to impart natural curvature to the diseased femoropopliteal artery, to promote swirling flow and elevate wall shear, which has a protective effect on the endothelium.1,2, 3 The helical shape of the stent is also designed to facilitate shortening of the stented segment during knee flexion and mitigate the risk of stented segment compression causing localized strains that in a straight stent may lead to stent fracture and chronic vascular injury.5, 6

Key components of the PMA application were the 12-month interim safety and effectiveness results from the company’s MIMICS-2 clinical study. The study was conducted under an FDA-approved Investigational Device Exemption (IDE) in patients with peripheral arterial disease (PAD) undergoing endovascular intervention in the femoropopliteal artery.

The company said BioMimics 3D represents an innovative approach to the requirement for durable support for the arterial lumen after intervention. The helical centerline stent is designed to not only promote swirling blood flow but also to accommodate the complex biomechanical challenge associated with stenting this anatomically mobile artery.

The MIMICS-2 study enrolled 271 subjects across 43 investigational sites in the U.S., Japan and Germany. The principal investigators are Timothy M. Sullivan, M.D., Minneapolis; Masato Nakamura, M.D., Ph.D., Tokyo, Japan; and Thomas Zeller, M.D., Bad Krozingen, Germany.

Both primary endpoints in the MIMICS-2 study, safety and effectiveness, were met. Freedom from major adverse events at 30 days was 99.6 percent (268/269) and Kaplan-Meier (KM) estimates of freedom from loss of primary patency and clinically-driven target lesion revascularization (CDTLR), were 83 percent and 88 percent, respectively, at 12 months; no stent fractures were detected in core laboratory imaging review.4                

For more information:



  1. Zeller T. - Oral Presentation VIVA 2014
  2. Malek, JAMA, 282, p 2035-2042, 1999
  3. Zeller T. et al; Circ Cardiovasc lnterv. 2016;9:e002930. DOI: 10.1161 2
  4. Data on file at Veryan Medical
  5. BH Smouse et al, Endovasc. Today, vol 4, no. 6, pp. 60-66, 2005
  6. Scheinert D et al, J Am Coll Cardiel 2005;45:312-5 doi:10.1016/j.jacc.2004.11.026

Related Content

Shockwave Initiates U.S. Pivotal Study for Coronary Intravascular Lithotripsy
News | Cath Lab | January 16, 2019
Shockwave Medical Inc. has initiated its U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE...
National Academy of Engineering, Ohio University Award 2019 Russ Prize
News | Cath Lab | January 03, 2019
Ohio University and the National Academy of Engineering announced the 2019 Fritz J. and Dolores H. Russ Prize will be...
Videos | Cath Lab | January 03, 2019
This is walk through inside one of the cardiac hybrid cath labs at the...
Videos | Cath Lab | January 03, 2019
This is the newest cardiac cath lab at the ...
Study Finds Effective Treatment for Coronary Slow Flow
News | Cath Lab | December 27, 2018
Patients who arrive at the hospital with heart-attack-like symptoms have had little recourse for their chest pain if...
Shockwave Announces Collaboration With Abiomed on Physician Training
News | Cath Lab | December 14, 2018
Shockwave Medical announced a new investment and collaboration agreement with Abiomed Inc. As outlined by the agreement...
Sponsored Content | Videos | Cath Lab | October 24, 2018
Michael Flaherty, M.D., discusses a study published in Circulation Research which finds that use of hemodynamic suppo
Philips Showcases Integrated Solutions for Cardiovascular Care at TCT 2018
News | Cath Lab | September 20, 2018
At the Transcatheter Cardiovascular Therapeutics (TCT) annual meeting, Sept. 21–25 in San Diego, Philips is showcasing...
Overlay Init